SELECTBIO Conferences 3D-Bioprinting, Biofabrication, Organoids & Organs-on-Chips Asia 2022

アジェンダ



同時開催される会議のアジェンダ

Flow Chemistry Asia 2022  |  3D-Bioprinting, Biofabrication, Organoids & Organs-on-Chips Asia 2022  |  Lab-on-a-Chip and Microfluidics Asia 2022  | 


2022年10月6日(木)


10月6日(木)のプログラムに関してはラボオンチップ、マイクロフルイディクスアジア2022のアジェンダをご参照ください

2022年10月7日(金)

08:00

展示ホールでのコーヒー&ティー、ネットワーキング

09:00

Danilo Tagle基調講演

NIHマイクロフィジオロジー・システム・プログラム。創薬とプレシジョンメディシンのツールとしての組織チップ
Danilo Tagle, Director, Office of Special Initiatives, National Center for Advancing Translational Sciences at the NIH (NCATS), United States of America

Approximately 30% of drugs have failed in human clinical trials due to adverse reactions despite promising pre-clinical studies, and another 60% fail due to lack of efficacy. A number of these failures can be attributed to poor predictability of human response from animal and 2D in vitro models currently being used in drug development. To address this challenges in drug development, the NIH Tissue Chips or Microphysiological Systems program is developing alternative innovative approaches for more predictive readouts of toxicity or efficacy of candidate drugs. Tissue chips are bioengineered 3D microfluidic platforms utilizing chip technology and human-derived cells and tissues that are intended to mimic tissue cytoarchitecture and functional units of human organs and systems. In addition toxicity studies in drug development, these microfabricated devices are also being used to model various human diseases for assessment of efficacy of candidate therapeutics. A more recent program is the development of “clinical trials on chips” to inform clinical trial design and implementation, and for studies in precision medicine. Presentation will provide a program update and future directions towards widespread use of tissue chip technologies in partnerships with various stakeholders.

09:30

Vascularature-on-a-Chip および Vascularized-3D-Model-on-a-Chip の電気化学的解析
梨本 裕司 東京医科歯科大学 生体材料工学研究所 准教授

During this decade, bioengineering technologies to make a perfusable vascular model and integrate it with a three-dimensional culture model shows great advancement. However, analytical systems to evaluate vascular function and its effects are still limited. In this presentation, the electrochemical platform to evaluate vascular permeability, topography, and the transvascular flow effects on 3D tissue will be demonstrated. The analytical platform is promising for read-outs of the functionality of the vascular model and vascularized 3D model in a microphysiological system.

10:00

上皮細胞・内皮細胞の界面設計によるマイクロフィジオロジーシステム(MPS)の構築
横川 隆司 京都大学 マイクロエンジニアリング専攻 教授

Microfluidic devices have become popular in many life science fields, including stem cell research. As a microfabrication scientist, I have been proposing new assay systems as microphysiological systems (MPS). The assay systems that mimic the functions of human biological organs can be constructed on a chip to measure physiological functions that are difficult to measure on a culture dish. We have employed two approaches to create the interface between organ cells and vascular networks in MPS: a two-dimensional method in which organ cells and vascular endothelial cells are co-cultured on the top and bottom surfaces of a porous membrane coated with an extracellular matrix, such as Transwell (2D-MPS), and a three-dimensional method in which the spontaneous patterning ability of vascular endothelial cells is utilized (3D-MPS). A 2D-MPS, renal proximal tubule model, evaluates albumin and glucose reabsorption and nephrotoxicity, while the glomerular filtration barrier model evaluates inulin and albumin filtration mechanisms. I will also present recent results on the development of a co-culture system of organoids and vascular network as a 3D-MPS. Kidney and brain organoids were cultured on a vascular network to demonstrate their maturation and vascularization. The on-chip vascular network is expected to expand from basic researches including vascular biology to evaluate the correlation between shear stress and vascular morphogenesis.

10:30

午前中のコーヒー&ティー、ネットワーキングイベント

11:00

Shoji Takeuchi基調講演

研究室から食卓へ:食肉生産のための3D組織工学
竹内昌治 東京大学 教授 統合バイオメディカルシステム国際研究センター、生産技術研究所

Research on "cultured meat," as typified by cultured hamburgers and chicken nuggets, has been studied world wide. These were made from randomly arranged muscle cells, so-called "minced meat." In contrast, our research group has been working on the in vitro fabrication of 3D structures of muscle tissue with the goal of realizing steak meat with its original texture. Bovine muscle tissue in the shape of a dice steak (1.0 cm x 0.8 cm x 0.7 cm) was prepared by forming a gel containing myoblasts grown from bovine muscle satellite cells into a sheet shape, stacking the sheet with both ends fixed to anchors, and culturing it. Myofibers in the tissue showed sarcomere-like structures stained with anti-a-actinin antibodies, suggesting that the myofibers were not just an aggregate of myoblasts, but that myoblasts fused with each other and underwent differentiation. In addition to these results, the latest developments will be presented in this talk.

11:30

Wai Yee Yeong基調講演

軟部組織の3D-バイオプリンティング:機能とプロセス
Wai Yee Yeong, Programme Director and Associate Professor, Nanyang Technological University, Singapore

The bioprinting landscape is expanding and growing with exciting new advances. Different bioprinting methods have been proposed to achieve functional and biological applications from the assembly of bioactive elements. In this talk, we will focus on 3D bioprinting of soft tissues with the focus on the key functional aspects of using 3D bioprinting. Beyond just creating the shapes, 3D bioprinting process is an innovative tool for aligning cells and recreating biomimetic design of soft tissues.

12:00

展示ホールでのネットワーキング・ランチ — 出展社訪問とポスター展示 — 弁当の昼食

14:00

前臨床試験における血管障害組織と疾患の3次元モデル化
Min Jae Song , Staff Scientist, National Center for Advancing Translational Sciences (NCATS), United States of America

In vitro three dimensional (3D) cellular models enable the study of multicellular interactions within functional tissue microenvironments. The enhanced physiological relevance of these complex 3D cellular models has opened the possibility of developing human-pathologically relevant disease assays for preclinical drug discovery and development studies. However, the increased cellular and structural complexity of these 3D cellular assays pose a significant technical challenge for their morphological and physiological validation, and use for pharmacological testing. Using 3D bioprinting techniques, we have established a robust and versatile method to engineer human vascularized tissues in a multiwell format. The bioprinting-based approach, used to biofabricate vascularized tissues, included a biodegradable polymer scaffold that enabled the addition of epithelia, in a transwell format. Several human barrier tissue models with vascularization were produced, including skin, peritoneal, and ocular tissues. Once 3D models of “healthy” tissues were biofabricated and validated, disease tissue models were developed by introducing disease-relevant chemical inducers or diseased cells, like cancer cells, into the “healthy” tissues. Treatments of the disease models with FDA approved drugs or drugs in clinical trials were able to correct the disease phenotypes. The structural, functional, and pharmacological validation of these tissues is critical to enable the use of these 3D models to accelerate the drug development process by providing pre-clinical data that it is more predictive of clinical outcomes.

14:30

CELLINK臓器オンチップデバイスの作製に向けたバイオプリンティングの新手法
吉江はるか CELLINK アプリケーションスペシャリスト

3D bioprinting has received much attention in recent years as more and more studies transition from 2D cell cultures to 3D cell cultures. Here, we present the bioprinting approach to fabricate microfluidic devices for organ-on-a-chip applications. There are different methods to create microchannel structures based on bioprinting technology. With the extrusion-based printing technology, channel structures are generally created with the sacrificial inks. Light-based printing technology such as digital light processing often enables printing of smaller and more complex structures. By mixing the biomaterials with cells, cell-embedding constructs with microfluidic channels can be bioprinted. Vascular models can be further implemented by post-print endothelial cell culturing on the wall of these microchannels to mimic the in vivo environment more closely. Using bioprinting technology, one can also print organoids. With continued developments, 3D bioprinting can offer great applications including vasculature studies and disease modeling.

15:00

光誘起3Dバイオプリンティング技術
Daniel Nieto, Head of Biofabrication and Tissue Engineering unit. , University of Santiago de Compostela, Spain

An overview of some photo curing-based bioprinting technologies, including Digital Light Projection, Volumetric bioprinting and a light-based biopen for biomedical applications is presented.

15:30

午後のコーヒー&ティーブレイクと展示ホールでのネットワーキング

16:00

Yong He基調講演

3Dバイオプリンティング:臓器モデルから組織修復まで
Yong He, Professor, Zhejiang University, China

In this talk, we reported the recent progress in 3D bioprinting of our group. 1) Standardizing the bioinks and a framework is given for the analysis of printability during projection based 3D bioprinting(PBP); 2) How to directly print cell-laden structures with effectively vascularized nutrient delivery channels? 3) How to mimic the complex extracellular matrix with near field direct writing?

16:30

議題は後日発表
亀井 謙一郎 京都大学 細胞統合システム拠点(iCeMS)特定拠点助教

17:00

自由形状で再構成可能な全水系3Dアーキテクチャの埋め込み印刷
Tiantian Kong, Associate Professor, Shenzhen University, China

Aqueous microstructures are challenging to create, handle and preserve since their surfaces tend to shrink into spherical shapes with minimum surface areas. The creation of freeform aqueous architectures will significantly advance the bioprinting of complex tissue-like constructs, such as arteries, urinary catheters and tracheae. We demonstrate the generation of complex, freeform, three-dimensional (3D) all-liquid architectures using formulated aqueous two-phase systems (ATPSs). These all-liquid micro-constructs are formed by printing aqueous bioinks in an immiscible aqueous environment, which functions as a biocompatible support and a pregel solution. By exploiting the hydrogen bonding interaction between polymers in ATPS, the printed aqueous-in-aqueous reconfigurable 3D architectures can be stabilized for more than 10 days by the non-covalent membrane at the interface. Different cells can be separately combined with compartmentalized bioinks and matrices to obtain tailor-designed tissue-like constructs with perfusable vascular networks. The freeform, reconfigurable embedded printing of all-liquid architectures by ATPSs offers unique opportunities and powerful tools since limitless formulations can be designed from among a breadth of natural and synthetic hydrophilic polymers to mimic tissues. This printing approach may be useful to engineer biomimetic, dynamic tissue-like constructs with spatially defined, vascularized networks.


Choose your language
English